154 Chapter 7 References 1. Lam JC, Gregson DB, Robinson S, Somayaji R, Conly JM, Parkins MD (2019) Epidemiology and outcome determinants of Staphylococcus aureus bacteremia revisited: a populationbased study. Infection 47(6):961–971 2. Souli M, Ruffin F, Choi SH, Park LP, Gao S, Lent NC et al (2019) Changing characteristics of Staphylococcus aureus bacteremia: results from a 21-year, prospective, longitudinal study. Clin Infect Dis 69(11):1868–1877 3. Holmes NE, Robinson JO, van Hal SJ, Munckhof WJ, Athan E, Korman TM et al (2018) Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia. BMC Infect Dis 18(1):107 4. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J et al (2020) Effect of vancomycin or daptomycin with vs without anAntistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA 323(6):527–537 5. Holland TL, Arnold C, Fowler VG Jr (2014) Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 312(13):1330–1341 6. Tong SYC, Lee TC (2020) Staphylococcus aureus bacteraemia: does duration matter? Lancet Infect Dis 20(12):1353–1354 7. Lambregts MMC, Molendijk EBD, Meziyerh S, Schippers EF, Delfos NM, Leendertse M, et al. Early differentiation between uncomplicated and complicated Staphylococcus aureus bacteraemia: potential value and limitations of a clinical risk score. Int J Clin Pract. 2020:e13601. 8. Dellinger RP (2003) Cardiovascular management of septic shock. Crit Care Med 31(3):946– 955 9. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30(4):633–638 10. Burrelli CC, Broadbent EK, Margulis A, Snyder GM, Gold HS, McCoy C et al (2018) Does the beta-lactam matter? Nafcillin versus cefazolin for methicillin-susceptible Staphylococcus aureus Bloodstream Infections. Chemotherapy 63(6):345–351 11. Flynt LK, Kenney RM, Zervos MJ, Davis SL (2017) The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections. Infect Dis Ther 6(2):225–231 12. Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Moine P et al (2020) A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. J Microbiol Immunol Infect 53(2):321–327 13. Monogue ML, Ortwine JK, Wei W, Eljaaly K, Bhavan KP (2018) Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia. J Infect Public Health 11(5):727–731 14. Youngster I, Shenoy ES, Hooper DC, Nelson SB (2014) Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Clin Infect Dis 59(3):369–375 15. Fani F, Regolisti G, Delsante M, Cantaluppi V, Castellano G, Gesualdo L et al (2018) Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury. J Nephrol 31(3):351–359
RkJQdWJsaXNoZXIy MTk4NDMw